Oral Targeted Therapies
We develop advanced oral targeted therapies for today’s most complex small molecules, including PROTACs, molecular glues, and other targeted protein degraders, by combining enabling technologies, high-potency containment, and direct access to specialists who tailor every decision to the needs of your molecule.
Potency meets progress
We specialize in the development and manufacturing of highly potent oral targeted therapies, supporting the full lifecycle from early formulation through to commercial launch. With more than 35 years of experience processing drug products containing HPAPIs, we bring together containment, formulation science, and enabling technologies to overcome the solubility, permeability, and bioavailability challenges common to modern targeted modalities.
Specialists in highly potent and complex molecules
Our facilities and teams are purpose-built to support the demanding requirements of targeted oral therapies. We operate with OEL capabilities down to 0.01µg/m3 (10ng/m³) and use advanced engineered containment and isolator technologies to ensure safety, control, and regulatory compliance. Dedicated high-potent suites support both development and commercial production, while our scientists bring deep expertise in HPAPI handling, particle engineering, and complex formulation at every stage of the program.
Complete integration
We act as your single point of contact across the entire CDMO journey, simplifying communication, accelerating timelines, and ensuring end-to-end continuity from drug substance through to patient supply.
- Early formulation & process development
- Access to enabling technologies for poorly soluble molecules
- Analytical method development & validation
- Clinical & commercial manufacturing
- Integrated high-potent packaging
- Global tech transfer and scale-up
- Regulatory support & safety compliance
Solubility. Solved.
TPDs (such as PROTACs, molecular glues, and SERDs) are often poorly soluble and highly challenging to formulate. Through our integrated development model, you gain direct access to a full suite of solubility-enhancing and bioavailability-enabling technologies, including spray drying, hot-melt extrusion (HME), particle engineering, micronization, and customized formulation strategies.
By selecting the right technology for each molecule’s unique physical and chemical profile, we help maximize exposure, improve manufacturability, and reduce the risk of late-stage reformulation.
From day one, you work directly with formulation, analytical, and process development experts who understand the challenges of modern targeted modalities. We do not force molecules into fixed platforms. Instead, we design a development pathway built around your compound’s specific risks, performance goals, and clinical strategy.
This approach delivers:
- Technology and process decisions driven by data, not predefined platforms
- Flexible, agile development models for poorly soluble and highly potent compounds
- End-to-end coordination for a seamless transition from development to commercial manufacturing
Non-Sterile Development & Manufacturing
World-leading science and minds supporting process development, formulation, and optimization on the pathway connecting your product to patients
Learn more about our non-sterile capabilities and how we deliver safe, reliable, and scalable solutions across a broad range of oral dosage forms.
Contact us today to talk to our expert customer services team about how we can support you with oral targets therapies services.